Core Insights - Longeveron Inc. is participating in the Global CardioVascular Clinical Trialists Forum, highlighting its focus on cellular therapies for serious medical conditions [2][3] Company Overview - Longeveron Inc. is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs [4] - The company's lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [4] - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [4] - The company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and Pediatric Dilated Cardiomyopathy (DCM) [4] - Laromestrocel has received five important FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for the HLHS program, and Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the Alzheimer's program [4] Event Participation - Dr. Joshua Hare and Dr. Nataliya Agafonova will participate in multiple panel discussions at the CVCT Forum, focusing on cell therapy in heart failure trials and the importance of cell delivery routes [2][3] - Specific topics include mesenchymal stem cell therapy for dilated cardiomyopathy and strategies to streamline cell therapy innovation [3]

Core Insights - Longeveron Inc. is participating in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, in New York, where management will hold one-on-one meetings with investors [1] Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to meet unmet medical needs [2] - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [2] - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [2] - Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty [2] - The development programs for laromestrocel have received five important FDA designations: - For the HLHS program: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation - For the Alzheimer's disease program: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [2]